NAME OF THE DRUG

CETROTIDE 250 µg, CETROTIDE 3 mg powder and solvent for injection. The active ingredient in CETROTIDE is cetrorelix, present as cetrorelix acetate.

Cetrorelix acetate is the acetate salt of a decapeptide with a sequence derived from LHRH and subsequently modified. Five of the ten amino acids present are in the D configuration. The peptide is protected from degradation by means of C- and N-terminal protective groups (acetyl and amide protection). The peptide sequence and chemical structure are as follows:

\[
\text{Ac-D-Nal-D-p-Cl-Phe-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH}_2
\]

The molecular formula is \( \text{C}_{70}\text{H}_{92}\text{ClN}_{17}\text{O}_{14} \) and the molecular weight is 1431.06. The CAS number is 130143-01-0.

DESCRIPTION

Cetrorelix acetate is an amorphous white powder, moderately soluble in water and poorly soluble in organic solvents.

CETROTIDE is a lyophilised powder for injection. The powder contains mannitol as excipient. The packs also contain solvent (Water for Injection) in pre-filled syringes.

PHARMACOLOGY

Pharmacotherapeutic group: LHRH-Antagonist, ATC code: H01CC02.

Cetrorelix is a luteinising hormone releasing hormone (LHRH) antagonist. LHRH binds to membrane receptors on pituitary cells. Cetrorelix competes with the binding of endogenous LHRH to these receptors. Due to this mode of action, cetrorelix controls the secretion of gonadotropins (LH and FSH).

Cetrorelix dose-dependently inhibits the secretion of LH and FSH from the pituitary gland. The onset of suppression is virtually immediate and is maintained by continuous treatment, without initial stimulatory effect.
In females, cetrorelix delays the LH surge and consequently ovulation. In women undergoing ovarian stimulation, the duration of action of cetrorelix is dose dependent. Following a single dose of 3mg of cetrorelix a duration of action of at least 4 days has been evaluated. On day 4 the suppression was approximately 70%. At a dose of 250µg per injection repeated injections every 24hr will maintain the effect of cetrorelix.

In animals as well as in humans, the antagonistic hormonal effects of cetrorelix were fully reversible after termination of treatment.

**Pharmacokinetics**

The absolute bioavailability of cetrorelix after subcutaneous administration is about 85%.

The total plasma clearance and the renal clearance are 1.2 mL•min⁻¹•kg⁻¹ and 0.1 mL•min⁻¹•kg⁻¹, respectively. The volume of distribution (V_{d,area}) is 1.1 L•kg⁻¹. The mean terminal half-lives following i.v. and s.c. administration are about 12h and 30h, respectively, demonstrating the effect of absorption processes at the injection site. The subcutaneous administration of single doses (250 µg to 3 mg cetrorelix) and also daily dosing over 14 days show linear kinetics.

**Clinical trials**

The efficacy and safety of cetrorelix in controlled ovarian stimulation followed by assisted reproductive techniques was studied in 6 phase II and 3 phase III studies (total 884 patients). There were three pivotal phase III trials: the first was an open randomised controlled trial of cetrorelix 250 µg per day and the LHRH agonist buserelin, both used with HMG. One hundred and eighty eight patients were treated with cetrorelix and 86 with buserelin. The second trial was an open uncontrolled study also of cetrorelix 250 µg per day, in 346 patients. The third study was an open randomised controlled study including cetrorelix 3 mg single dose and the LHRH agonist triptorelin; 115 patients were treated with cetrorelix and 39 with triptorelin.

All studies enrolled women aged 18-39 years with normal uterus and without abnormal ovarian or menstrual function. In the single dose study, the primary efficacy endpoint was defined as prevention of premature LH surge that might have lead to termination of the COS cycle; in the multiple dose studies the primary endpoint was whether or not triggering with HCG was performed. Other parameters evaluated included HMG dose, egg numbers, OPU, ET and pregnancy rates.

The studies concluded that both cetrorelix dosage regimens effectively prevented premature ovulation and luteinization when used with gonadotrophins in controlled ovarian stimulation, and were comparable to the LHRH agonists tested in this and other ART treatment outcome parameters evaluated.
INDICATIONS

Prevention of premature luteinization and ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques.

In clinical trials CETROTIDE was used with human menopausal gonadotropin (HMG), however limited experience with recombinant FSH suggested similar efficacy.

CONTRAINDICATIONS

- Hypersensitivity to cetrorelix acetate or any structural analogues of GnRH*, extrinsic peptide hormones or mannitol
- Pregnancy and lactation
- Post menopausal women
- Patients with moderate and severe renal and hepatic impairment

PRECAUTIONS

Luteal phase support should be given according to the reproductive medical centre’s practice.

During or following ovarian stimulation an ovarian hyperstimulation syndrome can occur. This event must be considered as an intrinsic risk of the stimulation procedure with gonadotropins.

As ovarian hyperstimulation syndrome can be life-threatening, the condition should be managed by a specialist experienced in the field.

There is limited experience up to now with the administration of CETROTIDE during a repeated ovarian stimulation procedure. Therefore CETROTIDE should be used in repeated cycles only after a careful risk/benefit evaluation.

Caution is advised in patients with hypersensitivity to GnRH. Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition. The treatment with Cetrotide is not advised in women with severe allergic conditions*.

Interactions with Other Drugs

In vitro investigations have shown that interactions are unlikely with medications that are metabolised by cytochrome P450 or glucuronised or conjugated in some other way. However, the possibility of interactions with commonly used medicinal products cannot entirely be excluded.

Use in Pregnancy

(Category D).

CETROTIDE is not intended to be used during pregnancy (see Contraindications). There is a theoretical risk of abortion if gonadotrophin releasing hormone antagonists are used during pregnancy. Studies in animals have indicated that cetrorelix increased the incidence of total fetal resorptions when administered to pregnant rats and rabbits during the period of organogenesis, at respective subcutaneous doses of 14.7 μg/kg/day and 6.8 μg/kg/day. Cetrorelix was not teratogenic in rats or rabbits at doses adversely affecting pregnancy.
Use in Lactation

CETROTIDE is not intended for use during lactation (see Contraindications). It is not known whether, or to what extent, cetrorelix is excreted into normal animal or human breast milk. Potential effects of cetrorelix on breastfed infants have not been determined and CETROTIDE should therefore not be used in breastfeeding women.

Carcinogenesis, mutagenesis and impairment of fertility

Long term carcinogenicity studies with cetrorelix have not been carried out. Cetrorelix showed no evidence of genotoxicity in assays for gene mutation in bacterial or mammalian cells. Tests for chromosomal damage in human lymphocytes in vitro and for micronucleus formation in mice in vivo showed that cetrorelix was not clastogenic. Cetrorelix induced binucleated cells and polyploidy in a strain of Chinese hamster lung cells in vitro, but this effect was not seen in human lymphocytes in vitro or in mouse bone marrow cells in vivo.

Cetrorelix treatment resulted in a reversible cessation of mating in female rats at a subcutaneous dose of 464 μg/kg/day and a reversible decrease in fertility in males at a dose of 68 μg/kg/day. These are expected pharmacological effects of this class of drug.

Effects on ability to drive and use machines

Due to its pharmacological profile cetrorelix is unlikely to impair the patient’s ability to drive or to operate machinery.

ADVERSE REACTIONS

The following definitions apply to the frequency terminology used hereafter:

Common $\geq 1/100, < 1/10$
Rare $\geq 1/10000, < 1/1000$

Clinical trial data

The safety of CETROTIDE in patients undergoing controlled ovarian stimulation was evaluated in 9 clinical studies. CETROTIDE was given in doses ranging from 0.1mg to 5mg as either a single or multiple dose.

The following table shows systemic adverse events from the beginning of CETROTIDE treatment until the day of embryo transfer at an incidence of $\geq 1\%$.

<table>
<thead>
<tr>
<th>Genitourinary: Ovarian Disorder</th>
<th>Cetrorelix Schedule</th>
<th>Reference Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple Dose Studies $\leq$0.5 mg/day</td>
<td>Single Dose Studies 3-5 mg/inj</td>
<td>Multiple Dose Studies n=86</td>
</tr>
<tr>
<td>n=635</td>
<td>n=187</td>
<td></td>
</tr>
<tr>
<td>28 (4.4%)</td>
<td>4 (2.1%)</td>
<td>7 (8.1%)</td>
</tr>
<tr>
<td>Neurological: Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 (1.3%)</td>
<td>0 (0.0%)</td>
<td>7 (8.1%)</td>
</tr>
<tr>
<td>Gastrointestinal: Nausea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 (1.3%)</td>
<td>2 (1.1%)</td>
<td>1 (1.2%)</td>
</tr>
</tbody>
</table>
Common: Local reactions at the injection site (eg erythema, bruising, itching, swelling and pruritus) were reported. Usually, they were of transient nature and mild intensity. In very rare cases, general reactions have been reported.

A single case of hot flushes with a causality assessment of “likely” was also recorded during treatment with cetrorelix in clinical trials.

A severe hypersensitivity reaction, associated with cough, rash and hypotension, was observed in one patient after 7 months of treatment of ovarian cancer with cetrorelix (10 mg/day). The patient recovered completely within 20 minutes. A causal relationship could not be excluded.

*Post-marketing data

Rare: systemic allergic/pseudo-allergic reactions including life-threatening anaphylaxis.

**DOSAGE AND ADMINISTRATION**

CETROTIDE should only be prescribed by or under the supervision of a specialist experienced in this field.

CETROTIDE is for subcutaneous injection into the lower abdominal wall.

The first administration of CETROTIDE should be performed under the supervision of a physician. It is advised that the patient be kept under medical supervision for 30 minutes to ensure there is no allergic/pseudo-allergic reaction to the injection. Facilities for the treatment of such reactions should be immediately available.

Subsequent injections with CETROTIDE may be self-administered as long as the patient is made aware of the signs and symptoms that may include hypersensitivity, the consequences of such a reaction and the need for immediate intervention.

**CETROTIDE 250 µg:**

The contents of 1 vial (250 µg cetrorelix) are to be administered once daily, at 24 hr intervals, either in the morning or in the evening.

**Administration in the morning:** Treatment with CETROTIDE 250 µg should commence on day 5 or 6 of ovarian stimulation (approximately 96 to 120hr after start of ovarian stimulation) with urinary or recombinant gonadotropins and is to be continued throughout the gonadotropin treatment period including the day of ovulation induction.

**Administration in the evening:** Treatment with CETROTIDE 250 µg should commence on day 5 of ovarian stimulation (approximately 96 to 108hrs after start of ovarian stimulation) with urinary or recombinant gonadotropins and is to be continued throughout the gonadotropin treatment period until the evening prior to the day of ovulation induction.

**CETROTIDE 3 mg:**

The contents of 1 vial (3 mg cetrorelix) are to be administered on day 7 of ovarian stimulation (approximately 132 to 144hr after start of ovarian stimulation) with urinary or recombinant gonadotropins.

If the follicle growth does not allow ovulation induction on the fifth day after injection of CETROTIDE 3 mg, 250 µg cetrorelix (CETROTIDE 250 µg) should be administered once daily beginning 96hr after the injection of CETROTIDE 3mg until the day of ovulation induction.
**Preparation for Administration**

As cetorelix is incompatible with several ingredients of common parenteral solutions it should be dissolved only by using water for injection.

CETROTIDE should only be reconstituted with the solvent provided, using a gentle, swirling motion. Vigorous shaking with bubble formation should be avoided.

Do not use if the solution contains particles or if the solution is not clear.

Withdraw the entire contents of the vial. This ensures a delivery to the patient of a dose of at least 230µg cetorelix (250µg strength) or 2.82mg cetorelix (3mg strength).

The solution should be used immediately after reconstitution.

Use in one patient on one occasion only. CETROTIDE contains no antimicrobial preservative.

The injection site should be varied daily.

**OVERDOSAGE**

Overdosage in humans may result in a prolonged duration of action but is unlikely to be associated with acute toxic effects.

In acute toxicity studies in rodents non-specific toxic symptoms were observed after intraperitoneal administration of cetorelix doses more than 200 times higher than the pharmacologically effective dose after subcutaneous administration.

Advise your patients to immediately contact their doctor or the Poisons Information Centre (in Australia telephone 131 126, in New Zealand telephone 0800 764 766) if they are concerned that they have given themselves too much CETROTIDE.

**STORAGE**

Store at 2°C to 8°C. (Refrigerate. Do not freeze). Protect from light.

**PRESENTATION**

CETROTIDE 250 µg:

Packs with 1 or 7 Type 1 glass vials each containing cetorelix 250µg (as cetorelix acetate) powder for injection, sealed with a rubber stopper.

In addition, for each vial the packs contain:

1 pre-filled syringe (Type 1 glass cartridge closed with rubber stoppers) with 1 mL solvent for parenteral use (Water for Injection)
1 injection needle (20 gauge)
1 hypodermic injection needle (27 gauge)
2 alcohol swabs

After reconstitution with the solvent provided, the concentration of cetorelix is 250µg/mL.
CETROTIDE 3 mg:

Pack with 1 Type 1 glass vial containing cetrorelix 3mg (as cetrorelix acetate) powder for injection, sealed with a rubber stopper.

In addition, the pack contains:

1 pre-filled syringe (Type 1 glass cartridge closed with rubber stoppers) with 3 mL solvent for parenteral use (Water for Injection)
1 injection needle (20 gauge)
1 hypodermic injection needle (27 gauge)
2 alcohol swabs

After reconstitution with the solvent provided the concentration of cetrorelix is 1mg/mL.

SPONSOR

Cetrotide is supplied in Australia by:
Merck Serono Australia Pty Ltd
3-4/25 Frenchs Forest Rd
Frenchs Forest NSW 2086

Cetrotide is supplied in New Zealand by:
Healthcare Logistics
58 Richard Pearse Drive
Airport Oaks
Auckland

DATE

TGA Approved: 2 May 2007
Date of last Amendment: 25 May 2011

* = safety related changes